国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
Journal of International Oncology
2015年
10期
776-779
,共4页
肺肿瘤%免疫法,被动%抗体,单克隆
肺腫瘤%免疫法,被動%抗體,單剋隆
폐종류%면역법,피동%항체,단극륭
Lung neoplasms%Immunity,passive%Antibody,monoclonal
肺癌的常规治疗疗效有限，目前免疫治疗已成为肺癌治疗新选择。多个临床研究初步证实了伊匹木单抗、程序性死亡受体-1抗体、免疫细胞、细胞因子、黑色素瘤相关抗原 A3蛋白疫苗、BLP25脂质体疫苗、Belagenpumatucel-L 和多肽疫苗等对肺癌的治疗效果，且多数已进入Ⅲ期临床研究阶段，有望成为肺癌综合治疗的重要组成部分。
肺癌的常規治療療效有限，目前免疫治療已成為肺癌治療新選擇。多箇臨床研究初步證實瞭伊匹木單抗、程序性死亡受體-1抗體、免疫細胞、細胞因子、黑色素瘤相關抗原 A3蛋白疫苗、BLP25脂質體疫苗、Belagenpumatucel-L 和多肽疫苗等對肺癌的治療效果，且多數已進入Ⅲ期臨床研究階段，有望成為肺癌綜閤治療的重要組成部分。
폐암적상규치료료효유한，목전면역치료이성위폐암치료신선택。다개림상연구초보증실료이필목단항、정서성사망수체-1항체、면역세포、세포인자、흑색소류상관항원 A3단백역묘、BLP25지질체역묘、Belagenpumatucel-L 화다태역묘등대폐암적치료효과，차다수이진입Ⅲ기림상연구계단，유망성위폐암종합치료적중요조성부분。
Lung cancer is characterized by high malignancy and the majority of patients are diagnosed at the advanced or late stage.Chemoradiotherapy has insufficient effect on this malignant tumor.At present the immune therapy has become a new choice for lung cancer treatment.Ipilimumab,antibody to programmed death-1 ,immune cells,cytokines,melanoma-associated antigen A3 vaccine,liposomal BLP25,belagen-pumatucel-L and polypeptide vaccine have been proved effective for lung cancer through various clinical trials. Futhermore,most of them have been moved forward to phase Ⅲ clinical trials in order to get more strong evidence to support the immunotherapy incorporated into the multidisciplinary treatment of lung cancer.
